Why Repligen Stock Is In Focus After Q2 2026 Earnings

Repligen (RGEN) is back on investor radar after its second quarter 2026 results, which showed higher revenue than a year earlier alongside a sharp drop in net income and earnings per share.

This combination of top line growth and weaker profitability offers a fresh data point to reassess how Repligen stock fits into your portfolio, particularly with the latest buyback update also now available.

Repligen shares are trading at US$159.44, with a 7 day share price return of 11.03% and a 90 day share price return of 29.14%. The 1 year total shareholder return of 40.45% contrasts with weaker 3 and 5 year total shareholder returns. This suggests recent momentum has picked up after a tougher multi year period and the latest earnings and buyback updates are now feeding into how investors weigh growth against risk.

If Q2 results have you reassessing exposure to life sciences tools, this is a good moment to scan for other potential compounders via the Simply Wall St screener for 42 healthcare AI stocks

After a sharp move higher and with profitability under pressure, Repligen now asks investors to weigh recent momentum against what they are paying for future cash flows. Does the current valuation still leave enough upside for the risk?

Most Popular Narrative: 12.4% Undervalued

Repligen is trading at $159.44 against a widely followed fair value narrative of about $182, which frames the current rally as only part of the story.

Strong and sustained order growth across biopharma, CDMO, and capital equipment segments supported by record multi quarter book to bill ratios and a robust funnel positions the company for above market revenue increases as therapy pipelines expand and demand for advanced bioprocessing solutions rises.

Want to see what is powering that fair value for Repligen? The narrative leans heavily on accelerating earnings, rising margins, and a rich future profit multiple. The exact mix may surprise you.

Result: Fair Value of $182.05 (UNDERVALUED)

However, Repligen’s story can change quickly if funding for smaller biotech customers stays weak or if gene therapy and AAV headwinds continue to weigh on revenue and margins.

Another View On Repligen’s Valuation

The fair value narrative for Repligen points to a modest 9.3% discount to an estimated value of about $175.70. Yet the stock trades on a P/S ratio of 11.5x, which is much higher than the Life Sciences industry at 4.1x and peers at 4.7x, and well above a fair ratio of 5.8x. Is that premium a cushion or a risk if sentiment cools?

For a closer look at how this pricing gap stacks up against fundamentals and peers, start with the detailed multiple breakdown in the valuation tools on Simply Wall St. Then compare across sectors using the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed messages in the data are part of what makes Repligen interesting right now. Check the numbers yourself and move quickly to shape your own stance using our breakdown of 3 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Repligen?

If Repligen has sharpened your focus on where to put fresh capital, now is the time to widen your search and compare other opportunities side by side.

• Target potential mispricings by scanning 50 high quality undervalued stocks that combine strong fundamentals with room for a better market view.
• Strengthen your income stream by checking companies in the 8 dividend fortresses that aim to pair higher yields with resilience.
• Reduce portfolio stress by reviewing the 78 resilient stocks with low risk scores that score well on stability and financial strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.